Uncategorized

The new molecule shows promise for Parkinson’s treatment. Recent research in mouse models suggests that a new molecule might be able to tap into key neurochemical mechanisms and help treat Parkinson’s disease. https://www.medicalnewstoday.com/articles/new-molecule-shows-promise-for-parkinsons-treatment

The summary of our findings written in layman’s terms can be found in the press release from Parkinson’s UK. A promising molecule, called BT13, has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do. https://www.parkinsons.org.uk/news/bt13-molecule-offers-hope-halting-parkinsons

Our first paper describing the effects of a small molecule GDNF mimetic, a compound called BT13, in a cell-based model of Parkinson’s and in vivo was published last week in the Journal of Movement Disorders! https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.27943

GeneCode was selected to present PD development at the 17th edition of the Tech Tour 2019 Nordic Venture Forum in Copenhagen, 30th- 31st October. The competition was very strong, with over 140+ applications and 500 individual company assessments. https://techtour.com/events/2019/10/event-nordic-venture-forum-2019.html?pageId=3065876

GeneCode participated in the UTILE Brokerage, Partnering and Networking Event in Trieste on the 16-18 October. The workshop offered an exciting opportunity to meet potential investors and partners, show achievements, network, engage, and enhance business prospects. https://techtour.com/events/2019/10/event-utile-brokerage-investment-and-partnering-event.html

GeneGode participated in the UTILE Partnering Summit on 11 July in London. About 1200 projects were reviewed and only a small percentage of those were scored highly in terms of potential for use of results or commercialisation and had the opportunity to participate and make a presentation https://www.eventbrite.com/e/utile-partnering-summit-london-registration-63154755574

We have recently published a peer-review article on GDNF mimetics in pain (07.07.17): Sidorova et al., 2017. A Novel Small Molecule GDNF Receptor RET Agonist, BT13, Promotes Neurite Growth from Sensory Neurons in Vitro and Attenuates Experimental Neuropathy in the Rat. Front. Pharmacol., 21 June 2017, Volume 8, Article 365, https://doi.org/10.3389/fphar.2017.00365

We have also published a paper on a preprint server called BioRxiv (01.07.17). Bespalov et al., 2016. The novel agonist of the GDNF family ligand-receptor RET for the treatment of experimental neuropathy. BioRxiv. doi: https://doi.org/10.1101/061820.

The newest Genecode scientific article about Parkinson’s (19.02.17) The newest Genecode scientific article about Parkinson’s was published in February 2017 in the UK ADJACENT Government journal where neurodegenerative diseases were the highlighted topic. In our article Protecting and restoring dopaminergic nerve cells in Parkinson’s disease you can read more closely about how, with the protection…

Participation at 10th Annual European Life Science CEO Forum & Exhibition (04.01.17) Genecode will be present with a tabletop exhibition at the 10th Annual European Life Science CEO Forum & Exhibition, 6-7 March 2017, Hilton Zurich Airport Hotel. Please visit us! http://www.sachsforum.com/10elsceo-about.html